此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

小儿实体瘤的综合组学分析及相关生物学研究库的建立

2026年10月15日 更新者:National Cancer Institute (NCI)

Background:

- Laboratory investigators who are studying common childhood cancers are interested in developing a tissue repository to collect and store blood, serum, tissue, urine, or tumors of children who have cancer or adults who have common childhood cancers. To develop this repository, additional samples will be collected from children and adults who have been diagnosed with common childhood cancers such as leukemia and tumors of the central nervous system.

Objectives:

- To collect and store blood, serum, tissue, urine, or tumor samples of children who have cancer or adults who have common childhood cancers.

Eligibility:

  • Individuals who have been diagnosed with a common childhood cancer (e.g., leukemia) regardless of patient age.
  • Children, adolescents, and adults who have been diagnosed with a type of cancer more commonly found in adults.

Design:

  • Extra blood, serum (the liquid part of blood), tissue, urine, or tumor samples will be collected from participants at a time when sampling is required for medical care or as part of a research study.
  • No additional procedures will be performed for the sole purpose of obtaining additional tumor tissue, aside from what is required for clinical care.

研究概览

详细说明

Background:

-Laboratory-based investigations have contributed to an improved understanding of the biology of cancer and to the development of new therapies for pediatric malignancies.

Objectives:

-Systematic Molecular, Genomic, Proteomic, Metabolomic ("Omic") and other profiling for enrolled subjects where omics refers to mechanistic studies using a set of advanced technologies to capture comprehensive aspects of biological systems providing insights into structure, function and interactions to understand these complex processes and diseases better.

Eligibility:

Pediatric or Adult subjects of any age with one of the following:

  • Diagnosis of any tumor or malignancy, pre-malignant disorder or suspected cancer susceptibility familial syndromes, regardless of age
  • Individuals without malignancy undergoing surgery, other treatment such as apheresis or normal well visit or routine blood draw as part of standard of care.
  • Biological relatives of a subject with a tumor or malignancy (pediatric or adult) or with suspected familial cancer syndrome. Patients enrolled in an approved companion protocol
  • Blood and/or tissue specimens that have been previously collected and are available for research analysis
  • Biospecimens can be collected with minimal additional risk to the subject during sampling or procedures required for routine patient care.

Design:

  • This study will allow for the collection of specimens for a Tissue Repository, and for designated sample investigations including systematic molecular, genomic and proteomic (Omic) profiling, and growth factor and cellular profile investigations.

  • Testing activities may include:

    • DNA, RNA and protein extracted from a section of tumor and normal samples; the remainder will be stored.
    • Germ line DNA and RNA extracted from lymphocytes or other normal uninvolved tissue
    • Germ line DNA will be extracted from lymphocytes or other normal uninvolved tissue of relatives of the subject.
    • Xenografts, explant and cell lines established from tumor, pre-malignant and normal samples
    • Tumor samples and samples for circulating tumor cells sent for the establishment of Xenografts and single cell suspension of tumor for drug testing or for monitoring cell free DNA over time
    • Omics (Genomics and Proteomic) studies will be performed
    • Growth factor and cellular profile investigations of bone marrow-derived cell populations to include quantification of hematopoietic progenitor cells (HPCs), endothelial progenitor cells (EPCs), and mesenchymal progenitor cells (MPCs), levels of matrix metalloprotease 2 and 9 (MMP2) and (MMP9), gene expression, growth factor and microvesicle analysis and bone marrow analysis of progenitor cells in blood and tissue.
    • Research tests described in active IRB approved protocols.
    • Immune profiling and stromal profiling of blood, tumor, and normal tissues
    • Immune function studies from blood and normal tumor tissues.
  • Utilizing an oversight committee to oversee the receipt and the distribution of unlinked tissues to other investigators.

  • Qualitative methodologies will be used to ascertain knowledge, attitudes, beliefs, and behaviors in 25-35 parents/caregivers at NIH concerning the anticipated use of NGS for diagnosing and directing therapy for pediatric cancer and how incidental findings might be returned.

  • Expected accrual of 100-150 patients per year.

研究类型

观察性的

注册 (估计的)

6035

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • District of Columbia
      • Washington D.C.、District of Columbia、美国、20010
        • 完全的
        • Children's National Medical Center
    • Florida
      • Orange、Florida、美国、92613
        • 撤销
        • Children's Hospital of Orange County (CHOC Children's)
    • Maryland
      • Bethesda、Maryland、美国、20892
        • 招聘中
        • National Institutes of Health Clinical Center
        • 接触:
          • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
          • 电话号码:TTY dial 711 800-411-1222
          • 邮箱:ccopr@nih.gov
    • New York
      • New York、New York、美国、10029-0574
        • 撤销
        • Tisch Cancer Institute, Mount Sinai Medical Center
    • North Carolina
      • Charlotte、North Carolina、美国、28203
        • 撤销
        • Carolinas Medical Center/Levine Children's Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

4周 及以上 (孩子、成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Subjects with a diagnosis of any tumor or malignancy regardless of age, or without malignancy undergoing surgery, other treatment or normal well visit. Suspicion of a familial premalignant condition. Biological relatives of a subject with a pediatric or adult tumor or malignancy or with suspected familial cancer syndrome.

描述

  • SUBJECT INCLUSION CRITERIA:

Pediatric or adult subjects with one of the following:

  • Diagnosis of any tumor, malignancy, pre-malignant disorder, or suspected premalignant familial syndromes, regardless, of patient age;
  • Biological relatives of any patient with a tumor, malignancy, pre-malignant disorder, or suspected familial pre-malignant syndrome, regardless of patient age or the diagnosis of an adult malignancy or pre-malignant disorder;
  • Healthy Volunteer without history of malignancy nor a family member currently being treated for cancer who are undergoing surgery, treatment or during well visits;
  • Biospecimens can be collected with minimal additional risk to the subject during sampling or procedures required for routine patient care.
  • Human samples, specimens and data collected on IRB approved protocols that are now closed
  • Ability of subject, Legally Authorized Representative (LAR), or parent/legal guardian of children <=18 to understand and be willing to sign an IRB-approved informed consent document that permits the use of the tumor and other samples for genomic-based molecular characterization projects.

Inclusion Criteria for Social and Behavioral Outcome Interviews:

  • Parent/caregiver of a participating pediatric or adult patient who is being treated for, or who has previously been treated for any form of pediatric cancer.
  • Must be able to give consent and sign the informed consent document.
  • Able to understand the English language.

EXCLUSION CRITERIA:

None

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:OTHER

队列和干预

团体/队列
1/Cohort 1

Adult or Pediatric subjects, with any malignancy, pre-malignancy, suspected malignancy, family history of malignancy, or without malignancy undergoing surgery or well visit.

2/Cohort 2

Human samples, specimens and data collected on IRB approved protocols that are now closed

3/Cohort 3

Parent/caregiver of a participating pediatric or adult subject who is being treated for, or who has previously been treated for any form of pediatric cancer.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
tissue analysis
大体时间:ongoing

Perform systematic molecular, genomic, proteomic, metabolomics and other high throughput ( Omics ) profiling on tumor and normal tissues

ongoing

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Rosandra N Kaplan, M.D.、National Cancer Institute (NCI)

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2010年4月21日

研究注册日期

首次提交

2010年4月22日

首先提交符合 QC 标准的

2010年4月22日

首次发布 (估计的)

2010年4月23日

研究记录更新

最后更新发布 (实际的)

2026年10月16日

上次提交的符合 QC 标准的更新

2026年10月15日

最后验证

2026年10月13日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

All IPD recorded in the medical record will be shared with intramural investigators upon request. In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP.

IPD 共享时间框架

Clinical data available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.

IPD 共享访问标准

Clinical data will be made available via subscription to BTRIS and with the permission of the study PI. Genomic data are made available via dbGaP through requests to the data custodians.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅